Bone fractures and lumbar mineral density after renal transplantation. A long-term cross-sectional study.

Background: The purpose of this work was to investigate the association of vertebral and peripheral fractures 10 yr after grafting with bone metabolic markers and body mass density (BMD).

Patients And Methods: One hundred thirty-eight recipients with stable graft function were included in a cross-sectional study. Graft function, biochemical mineral metabolism markers and body mass density (DEXA) were measured.

Effects of a single, high oral dose of 25-hydroxycholecalciferol on the mineral metabolism markers in hemodialysis patients.

Vitamin D deficiency is common in dialysis patients with chronic kidney disease. Low levels have been associated with increased cardiovascular risk and mortality. We evaluated the administration of a high, single oral dose of 25-OH cholecalciferol (3 mg of Hidroferol, 180 000 IU) in patients on chronic hemodialysis.

Are low levels of 25-hydroxyvitamin D a risk factor for cardiovascular diseases or malignancies in renal transplantation?

Background: Observational studies in healthy people suggest an inverse relationship between 25-hydroxy-vitamin D (25(OH)D levels) and cardiovascular diseases and malignancies. We performed an observational prospective study in renal transplant recipients to investigate the effects of vitamin D deficiency on cardiovascular and malignancy risks.

Methods: From 389 renal transplant recipients, 331 with a functioning graft at 12 months were included in the study.

Chronic increase of bone turnover markers after biliopancreatic diversion is related to secondary hyperparathyroidism and weight loss. Relation with bone mineral density.

Background: Biliopancreatic diversion (BPD) is the most effective bariatric procedure. Around 70% of these patients have secondary hyperparathyroidism (SH) in the long term as a consequence of calcium and vitamin D malabsorption. This work was aimed to study the influence of SH on bone turnover and its relationship with bone mineral density (BMD).

Very early serum creatinine as a surrogate marker for graft survival beyond 10 years.

Background: Available studies of early serum creatinine (SCr) as a surrogate marker for long-term graft loss are multicenter, registry-based or limited to 5- to 7-year survival.

Methods: This was a single-center observational retrospective study. SCr during the first year post-kidney transplant as an independent variable in determining long-term (>10-year) graft survival in 754 first cadaver kidney transplants was assessed with univariate and multivariate models.

Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity.

Background & Aims: Vitamin D deficiency has been recently associated with the metabolic syndrome. However, it is not known whether this possible association of vitamin D deficiency with the metabolic syndrome is still present at very high degrees of obesity, as in morbidly obese patients.

Methods: Transversal, observational study that included 73 consecutive morbidly obese patients (body mass index 40 kg/m(2)).

Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study.

Background: This prospective study was designed to investigate the long-term evolution of bone mineral density (BMD) in kidney transplant recipients.

Methods: In 86 patients with functioning grafts, 65 on tacrolimus-based immunosuppression and 21 on cyclosporine-based immunosuppression, laboratory parameters and BMD measurements in lumbar spine (L2-L4) and femoral neck (FN) were performed by DEXA in the first month after transplantation (baseline) and yearly thereafter up to the fourth year.

Results: BMD did not change at 12 months in lumbar spine nor in the FN.

Clinical outcomes and C2 cyclosporin monitoring in maintenance renal transplant recipients: 1 year follow-up study.

Background: Cyclosporin A (CsA) concentration monitoring with 2 h post-dosing levels (C2) correlates with the incidence of rejection and graft outcome in de novo renal transplant patients. The advantages of this policy beyond the first 12 months remain a matter of debate. The purpose of the present work was to evaluate the C2 target ranges on CsA monitoring after the first year in stable kidney transplant patients.